#Ireland #Dublin #BPH Treatment #ProVerum #Ted Lamson

ProVerum Welcomes Dr. Ted Lamson as Special Advisor

ProVerum Limited, an innovative player in the medical device industry, has made a significant move by appointing Dr. Ted Lamson, Ph.D., as a Special Advisor. With a profound background in medical device innovation, Dr. Lamson's addition to the team is anticipated to greatly enhance the company’s efforts in developing effective solutions for the treatment of benign prostatic hyperplasia (BPH).

Dr. Lamson, who boasts over 30 years of industry experience, has a proven track record in steering medical innovations from conception through commercialization. He is well-known for his role as a co-founder of NeoTract and for co-inventing the UroLift System within the ExploraMed incubator, where he continues to contribute to groundbreaking advancements in medical technology. His engagement in advisory roles and board appointments for emerging firms also underscores his deep connection with the medical technology ecosystem.

Paul Bateman, CEO of ProVerum, expressed his enthusiasm about bringing Dr. Lamson on board, stating, "Ted's in-depth knowledge and understanding of the BPH market will be invaluable as we scale commercialization of the ProVee System and work to redefine the treatment landscape for people with BPH." This sentiment was echoed by Dr. Lamson, who remarked on his dedication to creating improved clinical paradigms for men suffering from BPH.

BPH is a prevalent condition affecting men, characterized by symptoms such as a frequent or urgent need to urinate, more frequent night-time urination, a weak urine stream, and incomplete bladder emptying. For many, the condition results in a lower quality of life, prompting over 12 million men in the United States to seek medical attention. As these symptoms typically worsen over time, innovative solutions like those offered by ProVerum are essential.

ProVerum, headquartered in Dublin, is dedicated to the creation of minimally invasive technologies aimed at treating BPH. Its flagship product, the ProVee System, has received FDA approval and is now commercially available in the U.S. The company's commitment to innovation in this field is evident not only in its products but also in its strategic appointments and partnerships.

Dr. Lamson’s seasoned expertise and leadership in the medical device sector align well with ProVerum’s mission to provide novel solutions for BPH. As the company continues to enhance its offerings, the insights and direction from its new Special Advisor could lead to substantial advancements in treatment options for men with this common condition.

For further updates on ProVerum and its innovative technologies, you can visit ProVerum Medical's website or follow them on social media platforms like X or LinkedIn.